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Abstract
Background: Whether pre-diabetes in the absence of hypertension (HTN) or dyslipidemia (DLP) is a risk factor for
occurrence of major adverse cardiovascular events (MACE) is not fully established. We investigated the effect of
impaired fasting glucose (IFG) alone and in combination with HTN, DLP or both on subsequent occurrence of
MACE as well as individual MACE components.
Methods: This longitudinal population-based study included 11,374 inhabitants of Northeastern Iran. The
participants were free of any cardiovascular disease at baseline and were followed yearly from 2010 to 2017. Cox
proportional hazard models were fitted to measure the hazard of IFG alone or in combination with HTN and DLP
on occurrence of MACE as the primary endpoint.
Results: Four hundred thirty-seven MACE were recorded during 6.2 ± 0.1 years follow up. IFG alone compared to
normal fasting glucose (NFG) was not associated with an increase in occurrence of MACE (HR, 0.87; 95% CI, 0.19–
4.02; p, 0.854). However, combination of IFG and HTN (HR, 2.88; 95% CI, 2.04–4.07; p, 0.000) or HTN + DLP (HR, 2.98;
95% CI, 1.89–4.71; p, 0.000) significantly increased the risk for MACE. Moreover, IFG + DM with or without HTN, DLP,
or both was also associated with an increase in the incidence of MACE.
Conclusion: IFG, per se, does not appear to increase hazard of MACE. However, IFG with HTN or HTN + DLP
conferred a significant hazard for MACE in an incremental manner. Moreover, IFG without HTN, adjusted for DLP,
can be associated with an increase in the risk for CVD- death.
Keywords: Dyslipidemia (DLP), Hypertension (HTN), Impaired fasting glucose (IFG), Major adverse cardiovascular
events (MACE), Pre-diabetes (pre-DM)
Background
Pre-diabetes (pre-DM) is often taken as a warning sign.
Individuals with pre-DM have a glycemic state that is
higher than normal but not high enough to be classified
as type 2 diabetes (T2DM). The pre-diabetes state is
characterized by impaired fasting glucose (IFG), im-
paired glucose tolerance (IGT), or HbA1c of 39 mmol/
mol (5.7%) to 46 mmol/mol (6.4%) [1]. The significance
of pre-DM is the associated risk for progression to
T2DM which is disproportionately greater at the higher
end of the pre-DM range and with the combined pres-
ence of IFG and IGT [1]. Pre-DM and T2DM are parts
of a continuous spectrum that share in their pathophysi-
ology, and are associated with a common phenotype that
includes obesity, hypertension (HTN), and dyslipidemia
(DLP) [2]. It is well established that aggregation of the
traditional cardiovascular (CV) risk factors such as HTN
and DLP in patients with T2DM is associated with the
increased risk of cardiovascular disease (CVD) and
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events [3, 4]. Furthermore, insulin resistance per se that
is present in the vast majority of individuals with T2DM
is associated with the increased risk of CVD independent
of other CV risk factors [5, 6].
In addition to T2DM, pre-DM is also associated with an
increased risk of CVD [7] [8]. Considering that traditional
CV risk factors are frequently present in individuals with
pre-diabetes, the question arises that to what extent is the
effect of pre-DM on CVD risk mediated by having pre-
DM alone or by the associated risk factors [9, 10]. Since
some studies did not fully adjust for concomitant CV risk
factors, their findings should be interpreted with caution.
Hence, whether pre-DM or IFG alone in the absence of
HTN or DLP or their combination carries increased risk
for CVD has remained an unanswered issue.
Therefore, we conducted a study using data from Gole-
stan Cohort Study (GCS) to investigate whether pre-
diabetes in the absence of HTN or DLP is a risk factor for
occurrence of major adverse cardiovascular events
(MACE) as well as its individual components. We also ex-
amined the risk for MACE conferred by diabetes in the
presence or absence of HTN or DLP. We further did the
analysis in which patients with IFG and DM are consid-
ered together in comparison with patients with NFG.
Methods
Study design and population
We extracted data from GCS a community-based pro-
spective cohort study that was launched in Northeastern
Iran [11]. The primary aim of GCS was to investigate
risk factors of esophageal cancer in this region. The GCS
enrolled temporary residents from the rural or urban
areas of this region who aged 40–75 years, and were free
from any upper gastrointestinal cancer. Participants in
this cohort were also followed for CVD outcomes. In
this analysis, we included data from a total number of
11,374 participants who had no current or previous his-
tory of any known CVD events and had complete infor-
mation on fasting blood sugar (FBS), blood pressure
(BP), and lipid profile at the time of recruitment (2010–
2012). The ethical review committees of the Digestive
Disease Research Institute of Tehran University of Med-
ical Sciences, the US National Cancer Institute, and the
International Agency for Research on Cancer approved
the study protocol. Before interview, the written in-
formed consent was obtained from each participant.
Baseline data were collected during an interview by a
trained general physician, either in the local language
(Turkmen) or in the national formal language (Persian),
depending on the participant’s preference. Questions
were asked about the age, residence area (urban or
rural), smoking status, alcohol consumption, history of
any heart disease, or any kind of cancer. Height, weight,
waist and hip circumference were measured using
standard methods, and body mass index (BMI) was cal-
culated. BP was measured twice, with a 10-min interval,
from both arms in the sitting position using Richter aus-
cultator sphygmomanometers. A trained technician col-
lected Blood samples (10 ml). In the urban area, the
samples were immediately processed in the central la-
boratory at the Golestan Cohort Study Center. In the
rural areas, blood samples were kept in refrigerators
(+4C), until they were transferred in cooling boxes to
the central laboratory; the maximum duration between
blood collection and final processing was 8 h. FBS, trigly-
ceride (TG), cholesterol, and high density lipoprotein
(HDL) were measured enzymatically in all individuals
[11].
Follow up
Participants were followed up by annual phone calls
from their date of recruitment until the first occurrence
of any CVD event, death from any cause, or end of the
study (March 2017). Each cohort member was also
instructed at the time of enrollment to contact the team
in case of certain conditions such as hospitalization or
development of a new major disease. These contacts
were registered and subsequently followed by a staff
member. In case a death, cancer or any CVD event was
reported, the GCS team visited the participant’s home
and the medical centers in which any major diagnostic
or therapeutic procedures were done. The team col-
lected all clinical reports, pathology reports and hospital
records. Follow-up assessed at the end of the Golestan
study was successful for over 99% of the study partici-
pants. If a death was identified, a general practitioner
visited the home of the deceased. Causes of death were
ascertained through verbal interview and investigation of
medical documents [12]. Using the collected documents,
two internists independently determined the cause of
death with ICD-10 codes. If the two were concordant, a
diagnosis was made. Otherwise, a third senior internist
determined the cause of death.
Definition of IFG, DM, HTN, and DLP
IFG was diagnosed when a participant did not have DM,
but had an FBS of 5.6 to < 7.0 mmol/L, according to the
American Diabetes Association criteria (ADA) [1]. DM
was defined as a self-reported diagnosis, or being treated
with glucose lowering drugs, or those with FBS ≥ 7
mmol/L. Normal fasting glucose (NFG) was defined as
FBS < 5.6 mmol/L. Hypertension was defined as self-
reported hypertension and currently taking antihyper-
tensive drugs, or systolic blood pressure (SBP) ≥140
mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg
based on the JNC-7 criteria [13]. DLP was defined as
fasting TG ≥1.69 mmol/L, or total cholesterol ≥6.20
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mmol/L, or HDL < 1.29 mmol/L in women and < 1.03
mmol/L in men, or receiving lipid lowering medications.
Definition of MACE
The primary outcome in the current analysis was the first
occurrence of any component of the 3-point MACE de-
fined as non-fatal myocardial infarction (MI), non-fatal
stroke, and CVD death. CVD death composed of death
due to coronary heart disease, stroke, or heart failure.
Statistical analysis
Data are presented as means (SE) and numbers (percent-
age). In all cases, final analysis was based on presence or
absence of a risk factor (or factors) in the DM, IFG, and
NGT groups using fully adjusted models. Student t-test
and Pearson χ2 (or Fisher Exact) tests were used to com-
pare continuous and categorical variables, respectively.
Risk analysis was conducted in patients with IFG, and
Poisson regression model was used to identify predictors
of MACE (non-fatal MI, and non-fatal stroke, and CVD
death). Regarding the time to event for MACE and its
components, Kaplan-Meyer method was used to esti-
mate the survival probabilities, and Cox proportional
hazard models were fitted to measure the hazard ratios.
Statistical analyses were performed with Stata software




In this study, we included 11,374 participants from the
Northern provinces of Iran who were free of any CVD
events at the time of recruitment. Among the cohort
1543 (13.6%) individuals had DM, 2410 (21.2%) had IFG,
and 7421 (65.3%) had normal fasting glucose (NFG).
Baseline characteristics of the study population are
demonstrated in Table 1. The mean age of the partici-
pants was 56.2 (0.1) years and 47.5% of them were men.
There was a significant difference in the age, sex, smok-
ing status, percentage of statin users, BMI, waist circum-
ference (WC), waist-to-hip ratio (W/H), SBP, DBP, FBS,
TG, Chol, low density lipoprotein (LDL), percentage of
subjects with DLP or HTN among the studied groups
(p < 007, all). Moreover, the comparison between NFG
and IFG showed a significantly higher prevalence of
HTN (44.2 vs. 34.7%; p, 0.000) and DLP (49.9 vs. 39.7%;
p, 0.000) in IFG group. Moreover, compared to NFG
group, the IFG group were older and had a significantly
Table 1 Baseline characteristics of the participants according to the glycemic status
Variables Total (N = 11,374) NFG (N = 7421) IFG (N = 2410) DM(N = 1543) p-value
Age (yr.)* 56.2 (0.1) 55.8 (0.1) 56.7 (0.2) 57.4 (0.2) 0.000
Sex (%M) 47.5% 48.4% 47.3% 43.2% 0.001
Smoking (%) 0.000
Past 7.9% 7.8% 8.8% 7.2%
Current 8.3% 9.2% 8.1% 4.3%
Never 83.8% 83.0% 83.1% 88.5%
Alcohol (%) 2.7% 2.7% 2.6% 3.1% 0.7
Statin (%)† 4.2% 2.7% 3.7% 12.5% 0.007
BMI (kg/m2) * 27.1 (0.1) 26.5 (0.1) 27.6 (0.1) 29.2 (0.1) 0.000
WC (cm) * 94.6 (0.1) 92.5 (0.2) 96.2 (0.3) 101.9 (0.3) 0.000
W/H* 0.43 (0.001) 0.43 (0.001) 0.44 (0.002) 0.47 (0.002) 0.000
SBP (mmHg) * 125.7 (0.2) 123.9 (0.2) 128.0 (0.4) 130.7 (0.5) 0.000
DBP (mmHg) * 77.6 (0.1) 76.8 (0.1) 78.4 (0.3) 80.0 (0.3) 0.000
FBS (mmol/L) * 104.8 (0.4) 87.7 (0.1) 108.1 (0.1) 181.3 (1.8) 0.000
TG (mmol/L) * 138.7 (0.9) 126.9 (1.0) 145.5 (1.9) 185.2 (3.8) 0.000
Chol (mmol/L) * 203.5 (0.5) 200.3 (0.7) 207.1 (0.9) 213.3 (1.2) 0.000
LDL (mmol/L) * 118.2 (0.5) 116.4 (0.7) 121.1 (1.0) 122.3 (1.3) 0.000
HDL (mmol/L) 61.5 (0.6) 61.2 (0.3) 61.4 (0.8) 62.6 (3.7) 0.7
DLP %* 5189 (45.4%) 2945 (39.7%) 1202 (49.9%) 1040 (67.4%) 0.000
HTN %* 4517 (39.6%) 2578 (34.7%) 1064 (44.2%) 860 (55.7%) 0.000
Data are presented as mean (standard error) and number (percentage)
Comparing NFG and IFG groups: * p = 0.000, †p = 0.007
BMI Body mass index, WC Waist circumference, W/H Waist to hip ratio, SBP Systolic blood pressure, DBP Diastolic blood pressure, FBS Fasting blood glucose, TG
Triglyceride, Chol Cholesterol, LDL Low density lipoprotein, HDL High density lipoprotein, DLP Dyslipidemia, HTN Hypertension
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higher level of BMI, WC, SBP, DBP, TG, cholesterol,
and LDL (p = 0.000, all). Participants with IFG were
more likely to use a statin medication than did the NFG
group (3.7 vs. 2.7%, p, 0.007).
IFG and CVD outcomes
Over a mean follow up of 6.2 (± 0.1) years, 437 MACE (283
CVD deaths, 57 non-fatal MI, and 97 non-fatal strokes)
were reported. CVD death comprised of 155 fatal MI, 101
fatal strokes, and 27 deaths due to heart failure.
Table 2 shows HRs and 95% CI of MACE according to
glycemic status, HTN, and DLP. The occurrence of
MACE was not significantly different between those with
IFG but without HTN or DLP compared to NFG partici-
pants who also did not have HTN or DLP (fully adjusted
HR, 1.07; 95% CI, 0.60–1.90; p, 0.817). However,
Table 2 Cox regression models predicting MACE according to glycemic status, HTN, and DLP
HR (95% CI) for incident MACE
Category Unadjusted model Adjusted model 1 Adjusted model 2a











































Category Unadjusted model Adjusted model 1 Adjusted model 2b
NFG/−HTN 1.0 1.0 1.0










































Category Unadjusted model Adjusted model 1 Adjusted model 2c
NFG/−DLP 1.0 1.0 1.0










































Model 1: adjusted for age + sex. Model 2a: adjusted for age + sex + BMI + smoking (Never as reference). Model 2b: adjusted for age + sex + BMI +
smoking (Never as reference) + DLP. Model 2c: adjusted for age + sex + BMI + smoking (Never as reference) + HTN. NFG Normal fasting glucose, IFG
impaired fasting glucose, HTN Hypertension, DLP Dyslipidemia
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compared to normoglycemic subjects without HTN or
DLP, the hazard for incidence of MACE increased in
normoglycemic participants with HTN +DLP (fully ad-
justed HR, 2.67; 95% CI, 1.79–3.98; p, 0.000), IFG +
HTN +DLP (fully adjusted HR, 2.98; 95% CI, 1.89–4.71;
p, 0.000), and diabetic patients in the presence or ab-
sence of HTN and DLP (fully adjusted HR, 4.63; 95% CI,
3.03–7.08; p, 0.000) and (fully adjusted HR, 4.51; 95%
CI, 2.65–7.68; p, 0.000), respectively. Moreover, to com-
pare dysglycemic subjects with normoglycemic counter-
parts, we pooled data from IFG + DM. The results
showed IFG +DM in the presence or absence of HTN
and DLP was also significantly associated with an in-
crease in the risk of MACE, (fully adjusted HR, 3.64;
95% CI, 2.50–5.31; p, 0.000) and (fully adjusted HR,
1.85; 95% CI, 1.20–2.85; p, 0.005), respectively. When
participants were categorized based on glycemic status
with the presence or absence of HTN alone, individuals
with IFG without HTN did not increase the hazard of
MACE compared to NFG without HTN (fully adjusted
HR, 1.20; 95% CI, 0.78–1.85; p, 0.400). However, there
was a significant increase in the hazard of MACE in the
normoglycemic individuals with HTN (fully adjusted
HR, 2.68; 95% CI, 2.01–3.56; p, 0.000), IFG +HTN (fully
adjusted HR, 2.88; 95% CI, 2.04–4.07; p, 0.000), and dia-
betic participants without and with HTN (fully adjusted
HR, 4.26; 95% CI, 2.95–6.16; p, 0.000) and (fully adjusted
HR, 4.38; 95% CI, 3.10–6.19; p, 0.000), respectively. Fur-
thermore, IFG + DM in the absence or presence of HTN
was significantly associated with the risk of MACE, (fully
adjusted HR, 2.15; 95% CI, 1.57–2.95; p, 0.000) and (fully
adjusted HR, 3.38; 95% CI, 2.51–4.54; p, 0.000), respect-
ively. HRs for MACE was also evaluated according to
glycemic status in the presence or absence of DLP.
Compared to the normoglycemic subjects without DLP
(NFG/−DLP), IFG/+ DLP and IFG/− DLP did not in-
crease the hazard of MACE (fully adjusted HR, 1.30;
95% CI, 0.92–1.84; p, 0.138) and (fully adjusted HR,
1.08; 95% CI, 0.76–1.53; p, 0.680), respectively. On the
contrary, DM/+DLP and DM/− DLP were significantly
associated with an increase in the hazard of MACE (fully
adjusted HR, 2.48; 95% CI, 1.83–3.35; p, 0.000) and (fully
adjusted HR, 2.35; 95% CI, 1.62–3.41; p, 0.000), respect-
ively. Moreover, dysglycemic individuals (IFG+ DM) in
the absence or presence of DLP significantly increased
the hazard of MACE (fully adjusted HR, 1.44; 95% CI,
1.08–1.91; p, 0.012) and (fully adjusted HR, 1.80; 95%
CI, 1.39–2.34; p, 0.000), respectively.
Upon adjustment with confounders, comparing to
NFG, IFG in the absence of HTN, DLP, or both did not
decrease MACE free survival (p > 0.05 for all compari-
sons). Moreover, DM even in the absence of HTN and
DLP significantly decreased the MACE free survival (p <
0.000 for all comparisons) (Fig. 1).
We next examined the effect of IFG with HTN, DLP, or
both HTN+DLP on the occurrence of individual compo-
nents of MACE in detail. Table 3 shows the effect of IFG
in the presence or absence of HTN+DLP on the occur-
rence of the individual components of MACE defined as
non-fatal MI, non-fatal stroke, and CVD-death. IFG in the
presence or absence of HTN +DLP did not increase the
risk for non-fatal MI compared with NFG in the absence
of HTN +DLP (fully adjusted HR, 1.19; 95% CI, 0.25–
5.68; p, 0.831) and (fully adjusted HR, 0.87; 95% CI, 0.19–
4.02; p, 0.854), respectively. However, IFG in the presence
of HTN+DLP was significantly associated with an in-
crease in the risk for non-fatal stroke (fully adjusted HR,
3.18; 95% CI, 1.35–7.47; p, 0.008) and CVD-death (fully
adjusted HR, 3.25; 95% CI, 1.84–5.74; p, 0.000). Moreover,
DM in the absence or presence of HTN+DLP, as well as
IFG +DM in the presence of HTN+DLP significantly in-
creased the risk for non-fatal stroke (fully adjusted HR,
3.44; 95% CI, 1.12–10.59; p, 0.031), (fully adjusted HR,
4.30; 95% CI, 1.90–9.72; p, 0.000), and (fully adjusted HR,
3.61; 95% CI, 1.75–7.45; p, 0.001), respectively. Addition-
ally, DM in the absence or presence of HTN+DLP signifi-
cantly increased the risk for CVD-death (fully adjusted
HR, 5.22; 95% CI, 2.71–10.03; p, 0.000) and (fully adjusted
HR, 5.94; 95% CI, 3.55–9.95; p, 0.000), respectively. Fur-
thermore, IFG +DM in the absence or presence of HTN+
DLP was significantly associated with an increase in the
risk of CVD-death (fully adjusted HR, 2.24; 95% CI, 1.33–
3.79; p, 0.003) and (fully adjusted HR, 4.35; 95% CI, 2.73–
6.94; p, 0.000), respectively.
The results indicated that IFG in the presence or absence
of HTN did not increase the risk for non-fatal MI com-
pared to NFG in the absence of HTN (fully adjusted HR,
1.58; 95% CI, 0.56–4.46; p, 0.389) and (fully adjusted HR,
0.71; 95% CI, 0.21–2.46; p, 0.590), respectively. However,
IFG in the presence of HTN significantly increased the risk
for non-fatal stroke (fully adjusted HR, 2.76; 95% CI, 1.40–
5.43; p, 0.003) and CVD-death (fully adjusted HR, 3.12; 95%
CI, 2.04–4.78; p, 0.000). Moreover, IFG in the absence of
HTN, adjusted for DLP, did significantly increase the risk
for CVD-death (fully adjusted HR, 1.65; 95% CI, 1.01–2.68;
p, 0.045). Furthermore, DM in the absence or presence of
HTN significantly increased the risk for non-fatal stroke
(fully adjusted HR, 3.41; 95% CI, 1.59–7.33; p, 0.002) and
(fully adjusted HR, 4.47; 95% CI, 2.30–8.69; p, 0.000), re-
spectively. IFG +DM in the presence of HTN was also as-
sociated with an increase in the risk for non-fatal stroke
(fully adjusted HR, 3.35; 95% CI, 1.89–5.94; p, 0.000). In
addition, DM in the absence or presence of HTN signifi-
cantly increased the risk for CVD- death (fully adjusted HR,
4.10; 95% CI, 3.20–7.81; p, 0.000) and (fully adjusted HR,
5.26; 95% CI, 3.46–7.10; p, 0.000), respectively. The results
also indicated a significant increase in the risk for CVD-
death in IFG +DM in the absence or presence of HTN
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(fully adjusted HR, 2.66; 95% CI, 1.82–3.90; p, 0.000) and
(fully adjusted HR, 3.84; 95% CI, 2.67–5.53; p, 0.000), re-
spectively (Supplementary Table 1).
IFG in the presence or absence of DLP did not increase
the risk for non-fatal MI and non-fatal stroke. However,
IFG in the presence of DLP significantly increased the inci-
dence of CVD-death (fully adjusted HR, 1.60; 95% CI,
1.04–2.37; p, 0.032). Moreover, DM in the absence or pres-
ence of DLP significantly increased the risk for CVD- death
(fully adjusted HR, 2.68; 95% CI, 1.71–4.20; p, 0.000) and
(fully adjusted HR, 3.13; 95% CI, 2.18–4.48; p, 0.000), re-
spectively. IFG +DM in the absence or presence of DLP
was also significantly associated with an increase in the risk
for CVD-death (fully adjusted HR, 1.65; 95% CI, 1.17–2.33;
p, 0.004) and (fully adjusted HR, 2.22; 95% CI, 1.62–3.05; p,
0.000), respectively (Supplementary Table 2).
Discussion
The major findings of the present study on composite
CVD outcomes (MACE) in a group of individuals with
IFG are that IFG, per se, in the absence of HTN and
DLP is not associated with an increase in the risk for
MACE. In contrast, IFG in the presence of HTN or
HTN +DLP is associated with an incremental and sig-
nificant increase in the risk for MACE. Further analyses
regarding the impact of IFG in the presence of HTN,
DLP, or HTN +DLP on the individual components of
MACE demonstrated that IFG in the presence of HTN
or HTN +DLP incrementally increases the risk for non-
fatal stroke and CVD-death. Additionally, the combin-
ation of IFG with DLP is associated with an increase in
the risk for CVD-death. As expected, DM in the absence
or presence of HTN, DLP, or both is significantly associ-
ated with an increase in the risk for MACE. Moreover,
pooled analysis of IFG + DM shows dysglycemic status
compared with normoglycemic condition increases the
risk for MACE even in the absence of other CV risk fac-
tors such as HTN and DLP.
Whether pre-DM, per se, is an independent risk factor
for CVD has been a matter of debate. In the current
Fig. 1 The cumulative event- free survival analysis for occurrence of MACE according to (a) glycemic status, HTN, and DLP, (b) glycemic status
and HTN, (c) glycemic status and DLP, (d) IFG, DM, HTN, and DLP alone. MACE; major adverse cardiovascular events, NFG; normal fasting glucose,
IFG; impaired fasting glucose, DM; diabetes mellitus, HTN; hypertension, DLP; dyslipidemia
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Table 3 Cox regression models predicting individual components of MACE according to glycemic status, HTN, DLP
Category HR (95% CI) for incident non-fatal MI
Unadjusted model Adjusted model 1 Adjusted model 2











































HR (95% CI) for incident non-fatal stroke
Category Unadjusted model Adjusted model 1 Adjusted model 2











































HR (95% CI) for incident CVD- death
Category Unadjusted model Adjusted model 1 Adjusted model 2











































Model 1: adjusted for age + sex, Model 2: adjusted for age + sex + BMI + smoking (Never as reference). NFG Normal fasting glucose, IFG Impaired fasting glucose,
HTN Hypertension, DLP Dyslipidemia
Hashemi Madani et al. BMC Cardiovascular Disorders          (2020) 20:113 Page 7 of 11
study, IFG in the absence of other CV risk factors did
not increase the risk for composite end-point of MACE.
However, IFG in the absence of HTN, adjusted for DLP,
significantly increased the risk for CVD- death. Likewise,
other longitudinal population-based studies, also did not
find any association between pre-DM alone and CVD
risk [14, 15]. Moreover, Barr et al. showed IFG is an in-
dependent predictor for CVD mortality [16]. However,
some studies have indicated that dysglycemia within
pre-diabetic glucose range was associated with an in-
crease in the risk for CVD [6, 17, 18]. Most studies have
suggested that impaired glucose tolerance (IGT) is a
stronger predictor than IFG for CVD events [19, 20].
But, a recently published study demonstrated the inci-
dence of MACE in patients with established coronary ar-
tery disease (CAD) and pre-DM, defined as either of IFG
or IGT, does not differ from those in patients with nor-
mal glycemic status [21]. Furthermore, a previous study
conducted to assess the risk of death according to the
different diagnostic glucose categories showed “fasting
blood glucose alone is not sufficient to predict mortality
related to hyperglycemia” They found in any category of
fasting glucose, an increase in the 2-h post-load glucose
is associated with a higher risk of mortality [22]. Like-
wise, results from a recent review suggested that IGT
and HbA1C correlate more with CVD risk than IFG
[23]. These inconsistencies might be due to differences
in analytical methods, different definitions for pre- dia-
betes, and ethnic origins of the participants included in
the studies.
It is generally agreed that individuals with pre-diabetes
or T2DM have higher than normal CV risk factors. This
is probably due to the fact that T2DM and pre-DM
share common underlying pathophysiologic disturbances
such as insulin resistance [2]. In our study, as expected,
participants with IFG had significantly higher BMI, WC,
SBP, DBP, TG, total cholesterol, and LDL compared to
normoglycemic subjects. Moreover, they were more
likely to have HTN and DLP than those with NFG. Simi-
lar results are frequently reported in previous studies in-
vestigating the presence of CV risk factors in individuals
with pre-DM [9, 10, 24].
Aggregation of CV risk factors in individuals with pre-
DM is known to place them at higher risk for CV events
[10]. In the current study we found that IFG when associ-
ated with HTN significantly increased the risk of compos-
ite end-point of MACE. This result is in line with the
results of some previous studies in which the coexistence
of pre-DM and HTN, but not pre-DM without HTN, sig-
nificantly increased the risk of CVD events [14, 15]. An-
other study showed that pre-DM defined as IFG or IGT
even in the presence of prehypertension, defined as SBP
between120 to 139 or DBP between 80 to 89mmHg, sig-
nificantly increases the risk for CVD events [25]. HTN is a
well-known and powerful risk factor for almost all differ-
ent types of CVD events [26]. Similarly, the current ana-
lysis indicated HTN alone in normoglycemic participants
is associated with higher HRs for both MACE and all indi-
vidual components of MACE. The reason why coexistence
of pre-DM and HTN, but not pre-DM without HTN,
leads to higher CVD events might reflect the fact that both
of them induce endothelial dysfunction and inflammation
through elevation of inflammatory factors such as tumor
necrosis factor α (TNF α) and intercellular adhesion
molecule-1 (ICMA-1) [27]. Hence, co-occurrence of
HTN, or even pre-HTN, with pre-DM results in higher
levels of inflammatory factors and more severe endothelial
damage conferring additive risk for subsequent occur-
rence of composite end-point of MACE.
DLP, characterized by elevated TG, low concentration
of HDL, and an increased number of small dense LDL,
plays a critical role in acceleration of atherosclerosis and
is reported as an important independent risk factor for
CVD [28]. Several studies have demonstrated that indi-
viduals with pre-diabetes have deranged lipid profiles
compared to normoglycemic subjects [9, 22]. The fre-
quent association of DLP with pre-DM, which may re-
flect the underlying insulin resistance, has led to
frequent treatment of DLP in the pre-diabetes [29, 30].
Despite of the importance of screening and treatment of
DLP in individuals with pre-diabetes, we have not found
studies that combined pre-DM and DLP together in the
analysis for predicting CVD risk. Nevertheless, when we
compared the impact of IFG plus DLP with that of NFG
without DLP, we found that coexistence of DLP and IFG
did not confer any additional risk for development of the
composite end-point of MACE. One possible explan-
ation for this finding is that individuals with IFG were
more likely to use statin compared to normoglycemic in-
dividuals. Nowadays, statin therapy is widely recom-
mended for both primary and secondary prevention of
CV disease in a wide range of individuals, even in those
without hyperlipidemia [31, 32]. Statins exert their bene-
ficial effects not only through lowering of LDL, but also
by improving endothelial function [33], reducing vascu-
lar inflammation [32, 34], and exerting antithrombotic
actions [35].
With regard to the addition of both HTN +DLP to
IFG, the present analyses showed an incremental in-
crease in the occurrence of composite end-point of
MACE. Although addition of DLP to IFG did not in-
crease the risk for MACE, co-existence of DLP +HTN
increased the risk for MACE even more than addition of
HTN alone to IFG. Our findings support the results of
previous studies showing that the risk of CV events asso-
ciated with co-existence of HTN and DLP, labeled as
“lipitation”, is greater than the sum of the CV risks for
HTN and DLP alone [36]. The interaction between these
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two risk factors occurs at the vascular endothelial level
and results in increased oxidative stress and endothelial
dysfunction, disproportionate vascular contractility, ele-
vation of BP in dyslipidemic patients, further elevation
of BP in hypertensive patients, and accelerates the devel-
opment and progression of atherosclerotic lesions [37].
A similar finding has been reported in a large recent
study conducted among patients with 5 years’ duration
of T2DM. The results of this study showed that patients
with T2DM who had no CV risk factors had little or no
excess risk of CVD events or death compared with gen-
eral population with no diabetes [38]. The findings high-
light the significance of control of CV risk factors both
in patients with pre-DM and T2DM.
Considering the effect of IFG combined with CV risk
factors on the individual components of MACE, we
found that IFG in the absence of HTN, adjusting for
DLP, significantly increased the risk for CVD-death.
Addition of HTN, or HTN +DLP to IFG was associated
with an incremental increase in the risk for non-fatal
stroke and CVD-death. In addition, IFG combined with
DLP alone significantly increased the risk for CVD-
death. The reason why IFG in the absence of HTN, but
not in the absence of both HTN and DLP did increase
the risk for CVD-death might be explained by the con-
founding effect of medications such as statin that has
been previously shown to be independently associated
with a decrease in the risk for CVD mortality [39].
As expected DM either alone or in combination with
HTN, DLP, or HTN +DLP significantly increased the
risk for composite end-pint of MACE as well as the indi-
vidual components of non-fatal stroke and CVD- death.
However, addition of HTN, DLP, or HTN+ DLP to DM
did not increase the risk for non-fatal MI. These incon-
clusive findings could be due to the small number of
events in each group. In addition, further use of statin
might protect participants with DM who also have
HTN, DLP, or HTN +DLP from some individual CV
events.
Moreover, dysglycemia (IFG + DM) either alone or
combined with HTN, DLP, or HTN+ DLP was associ-
ated with an increase in the risk for MACE. This finding
highlighted the fact that high glucose level of any degree
might have a significant adverse effect on CV outcomes.
This study has several strengths. This study investi-
gated the impact of IFG alone or combined with other
well-established CV risk factors such as HTN, DLP, or
HTN +DLP, on the occurrence of MACE. We included
an adequately large number of participants without any
known CVD at baseline and the study had 99% follow-
up of participants. In addition, we adjusted for multiple
confounding factors including most of the traditional
CVD risk factors. Finally, the occurrence of individual
CV outcomes, including non-fatal MI, non-fatal stroke,
and CVD-death, was assessed. Weaknesses include the
fact that, due to non-availability of 2 h post-prandial
blood glucose, the effect of only IFG as a component of
pre-diabetes could be examined. Although evidence
shows that IFG is useful for screening of pre-diabetes in
the general population, use of IGT and HbA1C might be
stronger predictors of cardiovascular events [20, 40]. Fi-
nally, considering the study design, the findings might
be subjected to unmeasured confounding factors. In
addition, risk factors were only measured at baseline.
Therefore, the impact of the changes could not be
evaluated.
Conclusion
In summary, although IFG, per se, did not increase the
risk for MACE, the association of IFG with HTN or
HTN+ DLP conferred a significant risk for composite
end-point of MACE and some individual components
such as non-fatal stroke and CVD- death in an incre-
mental manner. Moreover, IFG alone in the absence of
HTN, adjusted for DLP, significantly increased the risk
for CVD- death. These findings support the idea that
emphasis should be placed on identification and treat-
ment of multiple CV risk factors in people with pre-
diabetes.
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